Neos' ADHD Drug Won't Launch Until 2017 As FDA Requires Clinical-Commercial Bridging Study
This article was originally published in The Pink Sheet Daily
Complete response letter seeks assessment of food effect of Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets).
You may also be interested in...
The latest drug development news and US FDA highlights from our Performance Tracker.
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
The latest drug development news and highlights from our FDA Performance Tracker.
Senators ask the agency to address the “regulatory loophole” permitting telehealth companies to promote prescription drugs without disclosing side effects and question if FDA has enforcement authority over third-party social media influencer promotions.